People with mild Graves’ eye disease may see a temporary improvement in sharpness of vision and color perception after three months of selenium, but these benefits disappear by six months.
Claim Context
In patients with mild Graves’ ophthalmopathy, selenium supplementation (200 mcg/day for six months) is associated with a transient improvement in best-corrected visual acuity and color vision at three months, but these gains are not sustained at six months, suggesting a short-term effect on ocular function.
“At the three-month assessment, follow-up indicated a significantly higher BVA for the selenium group (median of 0.1, IQR 0 to 0.2 vs 0, IQR 0 to 0.1; p = 0.030) compared to the standard of care group. Additionally, the color vision demonstrated significant difference between groups, with the selenium group having a mean score of 14.9 (SD 0.37) compared to standard of care group (14.62, SD 0.73, p = 0.027). By the six-month follow-up, there was no significant difference in BVA and color vision between the two groups.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether selenium supplementation produces consistent short-term improvements in visual acuity and color vision in mild Graves’ ophthalmopathy across populations, and whether these effects are transient.
A systematic review and meta-analysis of all RCTs measuring visual acuity and color vision at three and six months in adults with mild Graves’ ophthalmopathy receiving selenium (200 mcg/day) versus placebo, stratified by baseline selenium status and disease duration.
Whether selenium causes transient improvement in visual function by reducing orbital inflammation during the first three months.
A double-blind RCT of 200 adults with mild Graves’ ophthalmopathy and confirmed serum selenium <120 mcg/L, randomized to 200 mcg/day selenium selenomethionine or placebo, with visual acuity and color vision tested at baseline, 1, 3, and 6 months using standardized charts and color plates.
Whether transient visual improvements after selenium use correlate with reduced risk of later visual field loss or optic nerve damage.
A prospective cohort study following 500 patients with mild Graves’ ophthalmopathy, measuring visual acuity and color vision at baseline, 3, and 6 months, and tracking optic nerve damage or visual field defects over five years, comparing those with and without transient selenium-related improvement.
Whether patients who experience transient visual improvement after selenium have different baseline antioxidant status than those who do not.
A case-control study comparing baseline serum glutathione and selenium levels in 100 patients who showed transient visual improvement at three months versus 100 who did not, adjusting for thyroid antibody levels.
Whether serum selenium levels correlate with visual acuity and color vision at a single time point in patients with mild Graves’ ophthalmopathy.
A cross-sectional analysis of 300 patients with mild Graves’ ophthalmopathy, measuring serum selenium and testing visual acuity and color vision at one visit.